Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
GENPREX stock logo
GNPX
GENPREX
$0.26
-1.2%
$0.28
$0.20
$3.97
$7.24M-0.54.14 million shs528,668 shs
IMV Inc. stock logo
IMV
IMV
$0.66
$0.48
$12.70
$9.63M0.95233,607 shs44,800 shs
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$0.01
-4.3%
$0.01
$0.00
$0.01
$18.51M-2.4825,943 shs5,000 shs
Metacrine, Inc. stock logo
MTCR
Metacrine
$0.58
$0.57
$0.30
$0.59
$24.75M-0.73225,834 shs83,889 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
GENPREX stock logo
GNPX
GENPREX
-2.24%+12.81%-10.61%+1.02%-86.47%
IMV Inc. stock logo
IMV
IMV
0.00%0.00%0.00%0.00%0.00%
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
-4.29%+1.52%+34.00%+34.00%+103.03%
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
Genprex stock logo
GNPX
Genprex
1.0371 of 5 stars
0.04.00.04.70.00.00.6
IMV Inc. stock logo
IMV
IMV
N/AN/AN/AN/AN/AN/AN/AN/A
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00
N/AN/AN/A
GENPREX stock logo
GNPX
GENPREX
0.00
N/AN/AN/A
IMV Inc. stock logo
IMV
IMV
0.00
N/AN/AN/A
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
0.00
N/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/A$0.15 per shareN/A
IMV Inc. stock logo
IMV
IMV
$330K0.00N/AN/A($0.69) per share0.00
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/A$1.36 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
GENPREX stock logo
GNPX
GENPREX
-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)
IMV Inc. stock logo
IMV
IMV
-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/A
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$110KN/A0.00N/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
-$62.21M-$1.03N/AN/AN/A-84.88%-59.33%N/A

Latest GNPX, LTUS, IMV, CHMA, and MTCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
GENPREX stock logo
GNPX
GENPREX
-$0.82-$0.26+$0.56-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/AN/A
IMV Inc. stock logo
IMV
IMV
N/AN/AN/AN/AN/A
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
Genprex stock logo
GNPX
Genprex
N/A
1.94
1.94
IMV Inc. stock logo
IMV
IMV
N/A
2.93
2.93
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
0.34
12.15
12.15

Institutional Ownership

CompanyInstitutional Ownership
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
GENPREX stock logo
GNPX
GENPREX
14.05%
IMV Inc. stock logo
IMV
IMV
15.37%
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
Metacrine, Inc. stock logo
MTCR
Metacrine
37.72%

Insider Ownership

CompanyInsider Ownership
Chiasma, Inc. stock logo
CHMA
Chiasma
8.30%
GENPREX stock logo
GNPX
GENPREX
8.47%
IMV Inc. stock logo
IMV
IMV
0.33%
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
Metacrine, Inc. stock logo
MTCR
Metacrine
13.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
GENPREX stock logo
GNPX
GENPREX
2027.82 million25.47 millionNo Data
IMV Inc. stock logo
IMV
IMV
9711.71 million11.67 millionOptionable
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
2302.64 billionN/ANot Optionable
Metacrine, Inc. stock logo
MTCR
Metacrine
1042.57 million36.70 millionNot Optionable

Recent News About These Companies

Hypersonic missiles and weapons
Best parental control app of 2024
Ukraine-Russia war - latest
US imposes new missile, drone-related sanctions on Iran
Classroom Technology
Train Control Network Project for China Rail
AN2 Therapeutics Inc ANTX
More Missiles for Asia
India’s Armed Drone Fleet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chiasma stock logo

Chiasma NASDAQ:CHMA

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

GENPREX stock logo

GENPREX NASDAQ:GNPX

$0.26 0.00 (-1.23%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$0.25 -0.01 (-2.76%)
As of 07:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

IMV stock logo

IMV NASDAQ:IMV

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Lotus Pharmaceuticals stock logo

Lotus Pharmaceuticals OTCMKTS:LTUS

$0.0067 0.00 (-4.29%)
As of 07/7/2025 10:24 AM Eastern

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

Metacrine stock logo

Metacrine NASDAQ:MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.